{"id":16650,"date":"2014-03-06T09:14:43","date_gmt":"2014-03-06T14:14:43","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=16650"},"modified":"2014-03-06T07:36:05","modified_gmt":"2014-03-06T12:36:05","slug":"tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650","title":{"rendered":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; <b>Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)<\/b> which is a biopharmaceutical company that specializes in the research and development of RNA interference is currently rated as a \u201cHold\u201d by TheStreet. The biopharmaceutical company controls a market cap of $412 million with a 30 day share moving average of 288,300.<\/p>\n<p style=\"text-align: justify;\">Its key strengths can be seen in its steady revenue growth that has been ongoing in the recent past accompanied with a solid financial position with reasonable debt levels. Its main weaknesses lie on its low growth rate in net income as well as weak operating cash flow.<\/p>\n<p style=\"text-align: justify;\"><b>Highlights of the Hold ratings<\/b><\/p>\n<p style=\"text-align: justify;\">Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) quarter revenue trails the industry average by 15.7% although it has improved by 0.1% when compared to the same quarter a year ago. Earnings per share continue to decline showing that the company\u2019s revenue growth has not trickled down the company\u2019s bottom line. Tekmira Pharmaceuticals net income has dropped by highs of 77% when compared to the same quarter a year ago.<\/p>\n<p style=\"text-align: justify;\">The solid financial position that Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) \u00a0commands is as a result of a zero debt to equity ratio as the company has no debt as of the moment. The company\u2019s turnover ratio is high at 3.02 demonstrating its ability to meet short term cash demands.<\/p>\n<p style=\"text-align: justify;\">The major downside at the moment is Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s declining earnings per share that is slightly lower compared to that of the same quarter a year ago. In the past two years the company has not been able to register a clear trend of positive earnings something that is of a great concern in Wall Street. The company\u2019s change in net income has severely underperformed when compared to the same quarter a year ago, also falling short of the biotechnology industry as well as that of the S&amp;P 500.<\/p>\n<p style=\"text-align: justify;\">Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) was one of the top gainer in Wednesday trading session moving up by highs of 29.72% to close the day at a high of $24.92.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) which is a biopharmaceutical company that specializes in the research and development of RNA interference is [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":16673,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[4911,4910],"stock_ticker":[],"class_list":["post-16650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-nasdaqtkmr","tag-tekmira-pharmaceuticals-corporation-nasdaqtkmr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) which is a biopharmaceutical company that specializes in the research and development of RNA interference is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-06T14:14:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png\" \/>\n\t<meta property=\"og:image:width\" content=\"290\" \/>\n\t<meta property=\"og:image:height\" content=\"102\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold\",\"datePublished\":\"2014-03-06T14:14:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png\",\"keywords\":[\"NASDAQ:TKMR\",\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\",\"name\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png\",\"datePublished\":\"2014-03-06T14:14:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png\",\"width\":290,\"height\":102},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650","og_locale":"en_US","og_type":"article","og_title":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR","og_description":"Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) which is a biopharmaceutical company that specializes in the research and development of RNA interference is [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-03-06T14:14:43+00:00","og_image":[{"width":290,"height":102,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png","type":"image\/png"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold","datePublished":"2014-03-06T14:14:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png","keywords":["NASDAQ:TKMR","Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650","url":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650","name":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png","datePublished":"2014-03-06T14:14:43+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.png","width":290,"height":102},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmr-rated-as-a-hold-16650#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) Rated as a Hold"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/16650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=16650"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/16650\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16673"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=16650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=16650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=16650"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=16650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}